GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Incannex Healthcare Ltd (STU:IQI) » Definitions » Total Liabilities

Incannex Healthcare (STU:IQI) Total Liabilities : €2.86 Mil (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Incannex Healthcare Total Liabilities?

Incannex Healthcare's Total Liabilities for the quarter that ended in Mar. 2024 was €2.86 Mil.

Incannex Healthcare's quarterly Total Liabilities increased from Sep. 2023 (€0.00 Mil) to Dec. 2023 (€3.20 Mil) but then declined from Dec. 2023 (€3.20 Mil) to Mar. 2024 (€2.86 Mil).

Incannex Healthcare's annual Total Liabilities declined from Jun. 2020 (€0.65 Mil) to Jun. 2021 (€0.47 Mil) but then increased from Jun. 2021 (€0.47 Mil) to Jun. 2022 (€1.31 Mil).


Incannex Healthcare Total Liabilities Historical Data

The historical data trend for Incannex Healthcare's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incannex Healthcare Total Liabilities Chart

Incannex Healthcare Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.69 0.58 0.65 0.47 1.31

Incannex Healthcare Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 2.73 - 3.20 2.86

Incannex Healthcare Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Incannex Healthcare's Total Liabilities for the fiscal year that ended in Jun. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.308+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=1.31

Total Liabilities=Total Assets (A: Jun. 2022 )-Total Equity (A: Jun. 2022 )
=24.651-23.343
=1.31

Incannex Healthcare's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.635+(0.228+1.942890293094E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=2.86

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=15.87-13.007
=2.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Incannex Healthcare Total Liabilities Related Terms

Thank you for viewing the detailed overview of Incannex Healthcare's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Incannex Healthcare (STU:IQI) Business Description

Traded in Other Exchanges
Address
8 Century Circuit Norwest, Suite 105, Sydney, NSW, AUS, 3000
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products.